| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SEATTLE—Mass spectrometry specialist Accium BioSciences and clinical research company Radiant Research recently announced the signing of a co-marketing agreement that will see the two companies combine their expertise in microdosing or Phase 0 analysis to provide more extensive clinical services worldwide. The partnership will effectively see the two companies become a one-stop shop in the growing area of pre-clinical and early clinical pharmacokinetics (PK) testing.
 
"Accium has identified and established a network of highly qualified and experienced companies that provide services critical to our analytical offering (i.e., 14C synthesis providers, animal testing facilities, clinical services providers)," says Mr. Michael Chansler, Accium's VP Business Development. "Radiant Research is a recognized and experienced clinical pharmacology provider known for its excellence in radiolabeled studies. By combining our respective service offerings, we can provide a 'Bundled Services' approach for our clients making it easier for contracting and insuring seamless quality processes."
 
Accium specializes in accelerator mass spectrometry (AMS) analytical services. AMS is a highly sensitive method used to identify very small amounts of tracer compounds as they pass through test subjects. Dr. Ali Arjomand, Accium president and COO, says this sensitivity is key for PK profiling.
 
"Since only 20 uL of blood or plasma is required for AMS measurement at each time point, a full PK profile can be determined from a single mouse or rat," he explains. This reduces the total number of animals required in a study and introduces less variability since all the time points are collected from a single animal. It also means that very little labeled drug is needed for human studies, reducing the risk to human volunteers.
 
Washington-based Radiant offers a suite of clinical trials services through more than 50 clinical research sites across the U.S.
 
According to Mr. Mike Lester, Radiant president and CEO, the relationship between the two companies will allow them to combine all aspects of microdosing studies.
 
"Microdosing technology is a new research tool that will significantly reduce clinical trial failures due to poor pharmacokinetic profiles," he explains. "While the applications of microdosing can be broad, Phase 0 testing allows for human pharmacokinetic data with reduced toxicology, CMC, and regulatory investment. The result is that researchers will know earlier if a drug development candidate has an adequate pharmacokinetic profile and help drug development companies move the right compounds into development."
 
The companies are confident the attomole sensitivities achievable with AMS and the extensive string of clinical research sites will combine to make an attractive package for pharmaceutical and biotechnology clients looking to leverage severely stretched financial and biological resources.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue